Calendario›BIIB›Benepali
Benepali
Benepali® PEN Patient Satisfaction Survey
Ensayo de BIOGEN INC. en Artritis reumatoide · Espondiloartropatias.
Más ensayos de: Artritis reumatoide.
- Fase
- no aplica
- Estado
- Completado
- Participantes
- 500
- Centros
- 38
- Fin del objetivo primario
- jun 2018
previstos
fecha real
Qué significa cada fase y cada estado.
Estudio observacional. Comenzó en ago 2017.
Qué mide
Porcentaje de participantes que estan "Muy satisfechos (4)" o "Satisfechos (3)" con la pluma prellenada Benepali (dia 1)
Cómo lo describe el promotor
En el documentoEn inglés, del registroThe main aim of this study is to ascertain general satisfaction among participants with rheumatic diseases with day-to-day use of the Benepali® prefilled pen by means of a standardised participant questionnaire. In addition, it is to be investigated whether differences exist in general participant satisfaction between participant groups who have undergone various prior treatment and/or have previous experience with application systems (participants new to the use of biologics, participants changing over from a prefilled injection or changing over from another pre-filled pen) and between participants of the various indication groups. Furthermore, the participants are to evaluate various aspects of using the Benepali® pre-filled pen based on their personal experience, such as e.g. handling, user-friendliness and features of the Benepali® pre-filled pen, as well as the effectiveness of the training on injection with the Benepali® pre-filled pen, based on participant satisfaction with the training received with the training pen and the evaluation of the training material received.
Más ensayos de BIIB
| Ensayo | Fase | Estado | Lectura de resultados |
|---|---|---|---|
| Diranersen · CELIA | Fase 2 | En marcha, sin reclutar | mar 2026 (real) |
| BIIB142 | Fase 1 | Reclutando pacientes | ago 2026 (prevista, ya pasada: sin actualizar en el registro) |
| Litifilimab · TOPAZ-2 | Fase 3 | En marcha, sin reclutar | sep 2026 (prevista, ya pasada: sin actualizar en el registro) |
| Litifilimab · TOPAZ-1 | Fase 3 | En marcha, sin reclutar | sep 2026 (prevista, ya pasada: sin actualizar en el registro) |
| Litifilimab · AMETHYST | Fase 2/3 | En marcha, sin reclutar | oct 2026 (prevista) |
| Natalizumab | no aplica | En marcha, sin reclutar | oct 2026 (prevista) |
Todos los de BIIB, en su ficha.
Ficha completa en ClinicalTrials.gov (NCT03327454), actualizada en oct 2018.